- Home
- HSTM vs NUVB Comparison
HSTM vs NUVB Comparison
Compare HSTM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSTM
- NUVB
- Stock Information
- Founded
- HSTM 1990
- NUVB 2018
- Country
- HSTM United States
- NUVB United States
- Employees
- HSTM N/A
- NUVB N/A
- Industry
- HSTM Computer Software: Programming Data Processing
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- HSTM Technology
- NUVB Health Care
- Exchange
- HSTM Nasdaq
- NUVB Nasdaq
- Market Cap
- HSTM 828.5M
- NUVB 837.0M
- IPO Year
- HSTM 2000
- NUVB N/A
- Fundamental
- Price
- HSTM $25.99
- NUVB $2.36
- Analyst Decision
- HSTM Hold
- NUVB Strong Buy
- Analyst Count
- HSTM 2
- NUVB 6
- Target Price
- HSTM $29.00
- NUVB $7.83
- AVG Volume (30 Days)
- HSTM 181.8K
- NUVB 4.1M
- Earning Date
- HSTM 08-04-2025
- NUVB 08-07-2025
- Dividend Yield
- HSTM 0.48%
- NUVB N/A
- EPS Growth
- HSTM 14.03
- NUVB N/A
- EPS
- HSTM 0.67
- NUVB N/A
- Revenue
- HSTM $295,211,000.00
- NUVB $14,355,000.00
- Revenue This Year
- HSTM $5.00
- NUVB $98.78
- Revenue Next Year
- HSTM $5.20
- NUVB $489.71
- P/E Ratio
- HSTM $38.84
- NUVB N/A
- Revenue Growth
- HSTM 3.50
- NUVB 900.35
- 52 Week Low
- HSTM $25.36
- NUVB $1.54
- 52 Week High
- HSTM $34.24
- NUVB $3.46
- Technical
- Relative Strength Index (RSI)
- HSTM 43.52
- NUVB 54.70
- Support Level
- HSTM $25.55
- NUVB $2.19
- Resistance Level
- HSTM $26.47
- NUVB $2.41
- Average True Range (ATR)
- HSTM 0.50
- NUVB 0.16
- MACD
- HSTM -0.01
- NUVB -0.01
- Stochastic Oscillator
- HSTM 42.66
- NUVB 34.21
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.